Molded bone augmentation by a combination of barrier membrane and recombinant human bone morphogenetic protein-2

Ectopic vascularized bone formation by human umbilical cord-derived mesenchymal stromal cells expressing bone morphogenetic factor-2 and endothelial cells

Mesenchymal stromal cells (MSCs) isolated from numerous tissues including human fetal tissue are currently used in cell therapy and regenerative medicine. Among fetal tissues, the umbilical cord (UC) is one of the sources for both MSCs and endothelial cells (ECs). To establish ectopic vascularized bone tissue formation, UC-derived MSCs and ECs were isolated. UC-MSCs expressing human BMP-2 (hBMP-2-MSCs) were generated using an adenoviral system to promote bone formation. These cells were then transplanted with Matrigel into the subcutaneous tissue of an immune deficient NSG mouse, and bone tissue was analyzed after several weeks. The osteogenic differentiation ability of MSCs was elevated by transduction of the hBMP-2 expressing adenoviral system, and vascularization of bone tissue was enhanced by human umbilical vein endothelial cells (HUVEC). In this study, our results provide evidence that MSCs and HUVECs from human umbilical cord are suitable cells to investigate bone tissue engineering. The results also suggest that the co-transplantation of hBMP2-MSCs and HUVECs may be a simple and efficient strategy for improving tissue generation and angiogenesis in bone tissue engineering using stem cells.

Application of a novel resorbable membrane in the treatment of calvarial defects in rats

Diplen-Gam (DG) is a novel absorbable guided bone regeneration (GBR) membrane. This study was designed to evaluate the capacity of bone repair of DG compared with that of Bio-Gide (BG). Critical size defects were created in both sides of the calcarium of 36 Sprague-Dawley rats. Defects were assigned to six groups and each group was subjected to one of the following treatments: (A1) unfilled defects, (A2) Bio-Oss (BO) grafts, (B1) DG membrane, (B2) BG membrane, (C1) DG membrane + BO grafts and (C2) BG membrane + BO grafts. The animals were killed at 2, 4, 8 and 12 weeks after the operation. The defects and surrounding tissues were examined by gross observation and X-ray examination. The paraffin sections were subjected to HE (hematoxylin and eosin) staining and IHC (immunohistochemistry) for bone morphogenetic protein-2 (BMP-2). The X-rays showed that, at 12 weeks, the DG and BG group exhibited more new bone formation than CSD blank group did; the BG group exhibited more new bone formation than the DG group did (t = 5.240, P = 0.035), the BG + BO group showed no significant differences in bone formation compared with the DG + BO group (t = 1.246, P = 0.339). By IHC staining, BMP-2-positive results could be seen inside the DG membrane, on the surface of the new bone, and inside the new bone. It can be suggested that BG membrane achieved better effects in guided bone regeneration compared with DG membrane. No significant differences were found between the two membranes in their bone healing ability when they are used with BO. Therefore, DG membrane shows clinical effectiveness, but should be used in combination with bone substitute.

A comparison study between periosteum and resorbable collagen membrane on iliac block bone graft resorption in the rabbit calvarium

BACKGROUND

To compare the different resorption patterns between resorbable membrane barrier and periosteum after iliac block bone grafting radiographically and histologically.

METHODS

Eighteen mature male rabbits weighing from 2.0 to 2.5 kg were used. The recipient site was the rabbit skull, and autogenous iliac bone was used as the grafting material. The harvested iliac block bones were divided in the following groups: autogenous iliac block bone with preservation of the periosteum (the periosteum group), autogenous iliac block bone covered with a resorbable collagen membrane (Biomesh®, Samyang Co, Korea) after removing the periosteum (the collagen membrane group), and autogenous iliac block bones with removal of the periosteum (the control group). In each experimental group, periosteum or resorbable collagen membrane of the donor site was fixed directed to the periosteum of the recipient site. The specimens were examined macroscopically, radiographically, histologically, and histomorphometrically at every 2, 4, and 8 weeks.

RESULTS

All groups presented excellent bone graft healing state without inflammation, dehiscence, or displacement. The radiolucency increased from mild to moderate in all groups over the experiment. The mean thickness of the upper end of the cortical iliac bone graft was statistically significantly different between the control group and the periosteum group, between the four-week and eight-week control group, and between the four- week and eight-week periosteum group (p & 0.05).

CONCLUSION

This study suggests that both the periosteum and the resorbable collagen membrane may help to prevent soft tissue infiltration into the bone graft and to reduce bone graft resorption compared to block graft alone.

The impact of ovariectomy and hyperglycemia on graft consolidation in rat calvaria

OBJECTIVE

Implant placement frequently depends on bone augmentation. However, the impact of systemic metabolic diseases on the consolidation of bone substitutes remains poorly understood. Our goal is to study the impact of ovariectomy and hyperglycemia on graft consolidation in rat calvaria.

MATERIAL AND METHODS

We determined a rat model in which methacrylate hemispheres filled with deproteinized bovine bone mineral were fixed on the calvaria. The first group received streptozotocin (STZ) to induce diabetes. The second group of animals underwent ovariectomy (OVX), causing osteoporosis. Control animals remained untreated, only receiving vehicle injections (STZ-control) but not sham operation, respectively. Specimens were assessed by histomorphometry and μCT.

RESULTS

Graft consolidation was similar between the two groups. The rate of new bone formation after 4 weeks was 0.61±0.53% in the STZ group (n=10) and 0.69±0.91% in the control group (n=8). After 8 weeks, the rates of new bone formation were 4.98±3.16% in the OVX group (n=7) and 2.35±1.30% in the control group (n=10). The volume occupied by the bone substitute was not affected by STZ or OVX treatment. The low amount of newly formed bone could not be quantified by μCT.

CONCLUSION

We conclude that neither STZ nor OVX altered the early phase of graft consolidation. Our findings are limited by the weak osteogenic potential of the rat calvaria in this augmentation model.

Assessment of the potential of growth factors for localized alveolar ridge augmentation: a systematic review

OBJECTIVE

To systematically assess the literature regarding the clinical, histological, and radiographic outcome of bone morphogenetic proteins (BMP-2, BMP-7), growth/differentiation factor-5 (GDF-5), platelet-derived growth factor (PDGF), and parathyroid hormone (PTH) for localized alveolar ridge augmentation.

MATERIAL AND METHODS

Five separate Medline searches were performed in duplicate for human and animal studies, respectively. The primary outcome of the included studies was bone regeneration of localized alveolar ridge defects or craniofacial defects.

RESULTS

In six human studies, BMP-2 affected local bone augmentation with increasing volume for higher doses. A majority (43 of 45) of animal studies using BMP-2 showed a positive effect in favour of the growth factor (GF). In six of eight studies, a positive effect was associated with the use of BMP-7. Only one animal study was included for GDF-5 revealing statistically significantly higher bone volume. Regarding PDGF, statistically significantly higher bone volume was observed in five of 10 included studies. Four animal studies using PTH revealed statistically significantly more bone regeneration compared with controls.

CONCLUSIONS

Differing levels and quantity of evidence were noted to be available for the GFs evaluated, revealing that BMP-2, BMP-7, GDF-5, PDGF, and PTH may stimulate local bone augmentation to various degrees. Human data for the potential of rhBMP-2 are supportive.

Bone regeneration using a naturally grown HA/TCP carrier loaded with rh BMP-2 is independent of barrier-membrane effects

The present study investigated whether bone regeneration and biomaterial replacement would be improved by loading of biogenous biphasic biomaterial scaffolds (HA/TCP ratio 30/70) with rhBMP-2, and whether the placement of three barrier membranes differing in structure and porosity (prototyped SLA Ti specimens, GORE RESOLUT Adapt specimens, and titanized TiMESH light specimens) would have a synergistic effect. A rabbit calvarial model was used for the implantation studies. Histological specimens were obtained after 12 weeks and evaluated quantitatively for differences between the various material combinations. Loading of the biomaterials with rhBMP-2 significantly enhanced the amount of regenerated bone and caused a pronounced biomaterial replacement. While BMP-induced bone had formed uniformly over the surgical defects, bone regeneration in the absence of BMP depends on bone promotion from the margins of the defects toward the center. No positive effect on bone regeneration was seen for any of the placed barrier membranes. While the present study had shown that rhBMP-2 loading significantly increases bone regeneration using the investigated biomaterial, barrier-membrane placement may be useful in predetermining the final shape of the regenerative site but provides no additional beneficial impact on the amount and quality of the bone regeneration induced by rhBMP-2.

The Application of Recombinant Human Collagen in Tissue Engineering

Collagen is the main structural protein in vertebrates. It plays an essential role in providing a scaffold for cellular support and thereby affecting cell attachment, migration, proliferation, differentiation, and survival. As such, it also plays an important role in numerous approaches to the engineering of human tissues for medical applications related to tissue, bone, and skin repair and reconstruction. Currently, the collagen used in tissue engineering applications is derived from animal tissues, creating concerns related to the quality, purity, and predictability of its performance. It also carries the risk of transmission of infectious agents and precipitating immunological reactions. The recent development of recombinant sources of human collagen provides a reliable, predictable and chemically defined source of purified human collagens that is free of animal components. The triple-helical collagens made by recombinant technology have the same amino acid sequence as human tissue-derived collagen. Furthermore, by achieving the equivalent extent of proline hydroxylation via coexpression of genes encoding prolyl hydroxylase with the collagen genes, one can produce collagens with a similar degree of stability as naturally occurring material. The recombinant production process of collagen involves the generation of single triple-helical molecules that are then used to construct more complex three-dimensional structures. If one loosely defines tissue engineering as the use of a biocompatible scaffold combined with a biologically active agent (be it a gene or gene construct, growth factor or other biologically active agent) to induce tissue regeneration, then the production of recombinant human collagen enables the engineering of human tissue based on a human matrix or scaffold. Recombinant human collagens are an efficient scaffold for bone repair when combined with a recombinant bone morphogenetic protein in a porous, sponge-like format, and when presented as a membrane, sponge or gel can serve as a basis for the engineering of skin, cartilage and periodontal ligament, depending on the specific requirements of the chosen application.